Evidence map›Paper›PMID 33889575›Full record

ArticleFrontiers in cell and developmental biology2021

Retinoic Acid Inhibits Tumor-Associated Mesenchymal Stromal Cell Transformation in Melanoma.

Qi Lou, Minyi Zhao, Quanhui Xu, Siyu Xie, Yingying Liang, Jian Chen, Lisha Yuan, Lingling Wang, Linjia Jiang, Lisha Mou and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. The IL-17 family in diseases: from bench to bedside.Signal transduction and targeted therapy · 2023
    Review
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Qi LouDepartment of Hematology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
Minyi ZhaoDepartment of Hematology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
Quanhui XuSun Yat-sen Memorial Hospital, RNA Biomedical Institute, Sun Yat-sen University, Guangzhou, China.
Siyu XieSun Yat-sen Memorial Hospital, RNA Biomedical Institute, Sun Yat-sen University, Guangzhou, China.
Yingying LiangShenzhen Lansi Institute of Artificial Intelligence in Medicine, Shenzhen, China.
Jian ChenSun Yat-sen Memorial Hospital, RNA Biomedical Institute, Sun Yat-sen University, Guangzhou, China.
Lisha YuanKey Laboratory of Stem Cells and Tissue Engineering, Zhongshan School of Medicine, Ministry of Education, Sun Yat-sen University, Guangzhou, China.
Lingling WangThe Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.
Linjia JiangSun Yat-sen Memorial Hospital, RNA Biomedical Institute, Sun Yat-sen University, Guangzhou, China.
Lisha MouHealth Science Center, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, China.
Dongjun LinDepartment of Hematology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
Meng ZhaoDepartment of Hematology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone marrow mesenchymal stem/stromal cells (BMSCs) can be transformed into tumor-associated MSCs (TA-MSCs) within the tumor microenvironment to facilitate tumor progression. However, the underline mechanism and potential therapeutic strategy remain unclear. Here, we explored that interleukin 17 (IL-17) cooperating with IFNγ transforms BMSCs into TA-MSCs, which promotes tumor progression by recruiting macrophages/monocytes and myeloid-derived suppressor cells (MDSCs) in murine melanoma. IL-17 and IFNγ transformed TA-MSCs have high expression levels of myelocyte-recruiting chemokines (CCL2, CCL5, CCL7, and CCL20) mediated by activated NF-κB signaling pathway. Furthermore, retinoic acid inhibits NF-κB signaling, decreases chemokine expression, and suppresses the tumor-promoting function of transformed TA-MSCs by prohibiting the recruitment of macrophages/monocytes and MDSCs in the tumor microenvironment. Overall, our findings demonstrate that IL-17 collaborating with IFNγ to induce TA-MSC transformation, which can be targeted by RA for melanoma treatment.

Indexed as

interferon-γinterleukin-17MSCretinoic acidtumor associated MSCtumor microenvironment

Identifiers

PMID33889575
PMCPMC8055950
OpenAlexW3151655529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.